Lyocontract: Great Point Partners Acquires German CDMO

• Great Point Partners, a healthcare investment firm, has acquired Lyocontract, a private German contract development and manufacturing organization (CDOM).

• The acquisition aims to scale up Lyocontract’s contract manufacturing capabilities and distribution reach.

Great Point Partners has made a strategic acquisition of Lyocontract, a private German contract development and manufacturing organization (CDMO). The announcement was made on Thursday, marking a significant move for the healthcare investment firm.

Lyocontract, based in Ilsenburg, Germany, has been in the drug development and production business since 2007. The company operates out of a single facility that offers aseptic liquid filling, freeze-drying, and packaging services. It specializes in the manufacturing of liquid and freeze-dried injectable drugs, which are shipped globally for both clinical and commercial use.

The production plant of Lyocontract, catering to customers in Germany and beyond, was built out between 2010 and 2011 and received its manufacturing license in 2012. Lyomark Pharma became the majority shareholder in Lyocontract back in August 2017. Both companies are privately held and will continue to be managed independently.

This acquisition deal is the first investment to be sourced and executed by Great Point’s London-based European team. The team aims to help growing healthcare companies establish a worldwide presence and enter the U.S. market.

David Slattery, senior vice president at Great Point, said in a statement, “Lyocontract has a strong track record of providing highly specialized and critically important manufacturing services to pharmaceutical companies, bringing a powerful combination of experience, expertise, and technological capabilities to all of its partnerships.” He added that this investment underscores Great Point’s dedication to backing exceptional, proven management teams in businesses with a competitive advantage.